|Articles|May 3, 2022
CATO SMS Unveils New Name; Allucent
Rebranding follows series of acquisitions and newly combined services in clinical development.
Advertisement
CATO SMS unveiled its new name, Allucent, to emphasize the company's spotlight on serving the specialized needs of small and mid-sized biotech companies.
This move follows a three-year series of strategic acquisitions, most recently of clinical research provider, Pharm-Olam. Now, Allucent is a unified organization with more than 30 years of experience, built to support small and mid-sized biotech companies with achieving breakthrough science.
Read more about the rebranding here .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement